{
    "organizations": [],
    "uuid": "3bc53cf8a8a7739814d91ed3f4883c5f5409fa42",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/22/globe-newswire-nuvectraa-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-6-2018.html",
    "ord_in_thread": 0,
    "title": "Nuvectra™ to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "PLANO, Texas, Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full 2017 on Tuesday, March 6, 2018 after market close.\nNuvectra will hold a conference call on Tuesday, March 6, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 1785806. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/ .\nA replay of the call will be available starting on March 6, 2018 through March 13, 2018. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 1785806. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.\nAbout Nuvectra Corporation\nNuvectra TM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita ® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com .\nCompany Contacts:\nNuvectra Corporation\nWalter Berger, COO & CFO\n(214) 474-3102\nwberger@nuvectramed.com\nInvestor Contacts:\nThe Ruth Group\nTram Bui / Brian Johnston\n(646) 536-7035 / 7028\ninvestors@nuvectramed.com\nSource:Nuvectra Corporation",
    "published": "2018-02-23T00:01:00.000+02:00",
    "crawled": "2018-02-23T01:51:12.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "plano",
        "texas",
        "nuvectra",
        "corporation",
        "nasdaq",
        "nvtr",
        "neurostimulation",
        "medical",
        "device",
        "company",
        "announced",
        "today",
        "release",
        "financial",
        "result",
        "fourth",
        "quarter",
        "full",
        "tuesday",
        "march",
        "market",
        "close",
        "nuvectra",
        "hold",
        "conference",
        "call",
        "tuesday",
        "march",
        "et",
        "discus",
        "result",
        "number",
        "domestic",
        "caller",
        "international",
        "caller",
        "conference",
        "id",
        "live",
        "webcast",
        "conference",
        "call",
        "available",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "http",
        "replay",
        "call",
        "available",
        "starting",
        "march",
        "march",
        "access",
        "replay",
        "dial",
        "domestic",
        "caller",
        "international",
        "caller",
        "enter",
        "access",
        "code",
        "webcast",
        "available",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "day",
        "following",
        "completion",
        "call",
        "nuvectra",
        "corporation",
        "nuvectra",
        "tm",
        "neurostimulation",
        "company",
        "committed",
        "helping",
        "physician",
        "improve",
        "life",
        "people",
        "chronic",
        "condition",
        "algovita",
        "spinal",
        "cord",
        "stimulation",
        "sc",
        "system",
        "first",
        "commercial",
        "offering",
        "ce",
        "marked",
        "fda",
        "approved",
        "treatment",
        "chronic",
        "intractable",
        "pain",
        "trunk",
        "limb",
        "innovative",
        "technology",
        "platform",
        "also",
        "capability",
        "development",
        "support",
        "indication",
        "sacral",
        "neuromodulation",
        "snm",
        "treatment",
        "overactive",
        "bladder",
        "deep",
        "brain",
        "stimulation",
        "db",
        "treatment",
        "parkinson",
        "disease",
        "addition",
        "neuronexus",
        "subsidiary",
        "design",
        "manufacture",
        "market",
        "technology",
        "neuroscience",
        "clinical",
        "research",
        "market",
        "visit",
        "nuvectra",
        "website",
        "company",
        "contact",
        "nuvectra",
        "corporation",
        "walter",
        "berger",
        "coo",
        "cfo",
        "wberger",
        "investor",
        "contact",
        "ruth",
        "group",
        "tram",
        "bui",
        "brian",
        "johnston",
        "investor",
        "source",
        "nuvectra",
        "corporation"
    ]
}